Genovate Biotechnology Co., Ltd.
TWSE
Closed
Jul 28, 2026
Day's Range
26.7052 wk Range
17.65Key Statistics
Symbol
4130
Name
Genovate Biotechnology Co., Ltd.
Currency
TWD
Exchange
TWSE
High
26.70000
Low
26.70000
Open
‪26.70‬
Last
‪26.70‬
Market Cap
3.65B
Pe Ratio
‪267.00‬
Volume
0
Average Volume
54.27K
Dividend Yield
‪0.36%‬
Change
0.00
Percent Change
0.00
Timestamp
2026-07-28
Close
26.70000
Today Range Start
‪26.70‬
Today Range End
‪26.70‬
52 Week Range Start
‪17.65‬
52 Week Range End
‪38.89‬
Type
Stocks
Country
Taiwan
Historical Data - 4130 - Genovate Biotechnology Co., Ltd.
Historical Data
Market Cap - 4130 - Genovate Biotechnology Co., Ltd.
Market Cap
2026-07-27
3.65B
2026-07-24
3.65B
2026-07-23
3.65B
2026-07-22
3.65B
2026-07-21
3.65B
2026-07-20
3.66B
2026-07-17
3.66B
2026-07-16
3.74B
2026-07-15
3.76B
2026-07-14
3.67B
Dividend - 4130 - Genovate Biotechnology Co., Ltd.
Dividend
2025-08-20
0.0980
Splits
2025-08-20
1020-for-1000 split (0.98039)
Splits - 4130 - Genovate Biotechnology Co., Ltd.
Earnings - 4130 - Genovate Biotechnology Co., Ltd.
Earnings
Balance Sheet - 4130 - Genovate Biotechnology Co., Ltd.
Balance Sheet
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
 Assets | 1.50B | 1.59B | 1.60B | 1.56B | 1.51B | 1.57B |
| Liabilities | 126.04M | 141.07M | 131.68M | 153.60M | 136.64M | 144.86M |
| Shareholders Equity | 1.38B | 1.44B | 1.46B | 1.41B | 1.37B | 1.42B |
Cash Flow - 4130 - Genovate Biotechnology Co., Ltd.
Cash Flow
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Operating Activities | - | - | - | - | - | - |
| Investing Activities | - | - | - | - | - | - |
| Financing Activities | - | - | - | - | - | - |
| End Cash Position | 169.04M | 221.60M | 180.03M | 194.16M | 198.44M | 223.21M |
| Income Tax Paid | - | - | - | - | - | - |
| Interest Paid | - | - | - | - | - | - |
| Free Cash Flow | -17.62M | 23.74M | 51.43M | -22.50M | -35.39M | 59.92M |
Income Statement - 4130 - Genovate Biotechnology Co., Ltd.
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 492.40M | 510.85M | 528.51M | 438.75M | 434.25M | 472.72M |
| Cost of Goods | 315.38M | 318.20M | 317.59M | 283.88M | 284.50M | 279.61M |
| Gross Profit | 177.02M | 192.64M | 210.91M | 154.87M | 149.75M | 193.10M |
| Operating Expense | - | - | - | - | - | - |
| Operating Income | 6.91M | 23.42M | 26.99M | -13.89M | -1.16M | 39.46M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | 13.45M | 31.06M | 30.82M | -9M | 3.56M | 40.75M |
| Income Tax | 1.77M | 5.36M | 1.49M | 3.32M | 3.19M | 2.02M |
| Net Income | 11.68M | 25.69M | 29.33M | -12.32M | 372K | 38.73M |
| EPS Basic | - | 0.21839 | 0.262136 | -0.106796 | 0.003348 | 0.349515 |
| EPS Diluted | - | 0.21839 | 0.262136 | -0.106796 | 0.003346 | 0.349515 |
| Basic Shares Outstanding | - | 118.30M | 112.65M | 111.12M | 111.11M | 111.11M |
| Diluted Shares Outstanding | - | 118.30M | 112.65M | 111.12M | 111.11M | 111.11M |
| Ebit | 14.13M | 31.57M | 31.09M | -8.72M | 3.82M | 41M |
| Ebitda | 52.88M | 69.41M | 67.62M | 27.36M | 39.63M | 76.18M |
| Net Income Continuous Operations | 13.45M | 31.06M | 30.82M | -9M | 3.56M | 40.75M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Recommendations - 4130 - Genovate Biotechnology Co., Ltd.
Recommendations
Profile - 4130 - Genovate Biotechnology Co., Ltd.
Profile
Mic Code
XTAI
Sector
Healthcare
Industry
Biotechnology
Employees
193
Genovate Biotechnology Co., Ltd. is a Taiwan-based healthcare company focused on the research, development, manufacturing, and sale of pharmaceutical products. The company operates as a fully integrated specialty drug maker, offering both finished dosage forms and active pharmaceutical ingredients. Its product portfolio spans treatments for infectious diseases caused by viruses and bacteria and extends across multiple therapeutic areas, including oncology, cardiovascular conditions, metabolic and alimentary tract disorders, dermatology, musculoskeletal and nervous system diseases, as well as respiratory and urinary system conditions. Genovate Biotechnology also develops controlled-release dosage formulations designed to improve treatment convenience and adherence. Beyond prescription medicines, the company is active in cosmetics and healthcare foods, addressing broader wellness and personal care needs. Serving hospitals, clinics, pharmacies, and other healthcare providers, it plays a meaningful role in Taiwan’s pharmaceutical and biotechnology market. Founded in 1982 and headquartered in Hsinchu, Taiwan, Genovate Biotechnology emphasizes integrated capabilities from R&D through commercial manufacturing to support the availability of specialized therapies and health-related products.
Profile Details
Type
Common Stock
Address
No. 1, Gongye 1st Road
City
Hsinchu City
Zip
30351
Country
Taiwan
Phone
886 3 598 2221
